Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (breast cancer adjuvant chemo-hormone therapy cooperative group) trial
- 31 March 1992
- journal article
- clinical trial
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 28 (2-3), 673-680
- https://doi.org/10.1016/s0959-8049(05)80123-6
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Adjuvant therapy of breast cancerEuropean Journal of Cancer and Clinical Oncology, 1991
- Adjuvant tamoxifen in postmenopausal stage II breast cancer five years onThe Lancet, 1990
- TAMOXIFEN AND THE UTERUS AND ENDOMETRIUMThe Lancet, 1989
- ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERSThe Lancet, 1989
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast CancerNew England Journal of Medicine, 1988
- Tumor nuclear grade, estrogen receptor, and progesterone receptor: Their value alone or in combination as indicators of outcome following adjuvant therapy for breast cancerBreast Cancer Research and Treatment, 1986
- Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancerBreast Cancer Research and Treatment, 1985
- Progesterone Receptors as a Prognostic Factor in Stage II Breast CancerNew England Journal of Medicine, 1983
- Cancer of the BreastNew England Journal of Medicine, 1980
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958